Company profile: Immunservice
1.1 - Company Overview
Company description
- Provider of interleukin-2-based immunotherapy solutions, developing biomimetic medicines, vaccines, and growth factors, and offering IL-2 bioactivity measurements and resources for diagnostic and pharmaceutical development. Focuses on human and animal immunotherapy and human cell therapy, enhancing immune cell proliferation and targeting cancer and virus cells.
Products and services
- Interleukin-2-Based Medicines: Immunservice develops biomimetic therapeutics based on interleukin-2 for market approval, targeting therapeutic applications in human and animal immunotherapy and human cell therapy
- Interleukin-2: This natural immune hormone underpins development of medicines, vaccines, and growth factors, enhancing immune cell proliferation and targeting cancer and virus cells
- Interleukin-2 Bioactivity Measurements: This specialized service offers bioactivity measurements of interleukin-2 to support research and development in diagnostic and pharmaceutical developments and other specialized applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Immunservice
Argenx
HQ: United States
Website
- Description: Provider of immunology therapies for severe autoimmune diseases and cancer, including efgartigimod, an investigational antibody fragment targeting FcRn for severe autoimmune diseases with pathogenic IgG autoantibodies; ARGX-117, a humanized sweeping antibody inhibiting C2 and downstream complement in IgM-driven diseases; and empasiprubart, a human IgG1 anti-C2 sweeping antibody with enhanced FcRn binding to improve C2 clearance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Argenx company profile →
Outlook Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical development focused on ophthalmic formulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Outlook Therapeutics company profile →
Calypso Biotech
HQ: Switzerland
Website
- Description: Provider of biopharmaceutical research and development focused on therapeutics for autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calypso Biotech company profile →
Intercell
HQ: Austria
Website
- Description: Provider of vaccine design and development for prevention and treatment of infectious diseases, leveraging proprietary technology platforms to discover and develop antigens and adjuvants. Founded in 1998 and headquartered in Vienna, Austria.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intercell company profile →
MolMed
HQ: Italy
Website
- Description: Provider of medical biotechnology research, development and clinical validation of novel anticancer therapies. The pipeline includes antitumour therapeutics in clinical and preclinical development, including Zalmoxis (TK), a cell-based therapy enabling bone marrow transplants from partially compatible donors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MolMed company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Immunservice
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Immunservice
2.2 - Growth funds investing in similar companies to Immunservice
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Immunservice
4.2 - Public trading comparable groups for Immunservice
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →